A case of severe pityriasis rubra pilaris with a dramatic response to apremilast

Long-term safety and tolerability of apremilast in patients with psoriasis: Pooled safety analysis for ≥156 weeks from 2 phase 3, randomized, controlled trials (ESTEEM 1 and 2)

Jeffrey Crowley, Diamant Thaçi, P. Joly et al. · Journal of the American Academy of Dermatology · 2017 · 192 citations · Full text

Pharmacy, Pharmacology, Pharmacotherapy +16

Epidemiologic, Clinicopathologic, Diagnostic, and Management Challenges of Pityriasis Rubra Pilaris

Nicholas A. Ross, Hye Jin Chung, Qiaoli Li et al. · JAMA Dermatology · 2016 · 84 citations · Full text

Medicine, Dermatology, Pathology +13

Treatment Options for Pityriasis Rubra Pilaris Including Biologic Agents

A. Brooke Eastham, Alisa N. Femia, Abrar A. Qureshi et al. · JAMA Dermatology · 2013 · 51 citations

Medicine, Dermatology, Pharmacotherapy +7

Treatment of Refractory Pityriasis Rubra Pilaris With Novel Phosphodiesterase 4 (PDE4) Inhibitor Apremilast

Ifat Zerin Krase, Kevin Cavanaugh, Clara Curiel‐Lewandrowski · JAMA Dermatology · 2015 · 33 citations · Full text

Medicine, Dermatology, Pathology +9